Michael Gelband’s Catalyst Pharmaceutical CPRX Stock Holding History

Michael Gelband’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-152,327	Closed	-$3M	–	1630
2025 Q3	$3M	Buy	152,327 +106,878	+235%	+$2.2M	0.03%	590
2025 Q2	$986K	Buy	+45,449	New	+$1.07M	0.01%	965
2024 Q1	–	Sell	-39,077	Closed	-$657K	–	1562
2023 Q4	$657K	Buy	+39,077	New	+$534K	﹤0.01%	961
2023 Q2	–	Sell	-121,122	Closed	-$2.01M	–	1911
2023 Q1	$2.01M	Buy	+121,122	New	+$2M	0.02%	873
2022 Q3	–	Sell	-203,993	Closed	-$1.43M	–	1935
2022 Q2	$1.43M	Buy	203,993 +182,242	+838%	+$1.34M	0.02%	927
2022 Q1	$180K	Sell	21,751 -39,564	-65%	-$280K	﹤0.01%	1935
2021 Q4	$415K	Sell	61,315 -10,194	-14%	-$67K	﹤0.01%	1511
2021 Q3	$379K	Buy	71,509 +45,191	+172%	+$247K	0.01%	1526
2021 Q2	$151K	Buy	+26,318	New	+$136K	﹤0.01%	2058
2021 Q1	–	Sell	-41,827	Closed	-$140K	–	2172
2020 Q4	$140K	Buy	+41,827	New	+$141K	﹤0.01%	1797
2020 Q3	–	Sell	-10,235	Closed	-$47K	–	1813
2020 Q2	$47K	Buy	+10,235	New	+$46K	﹤0.01%	1686

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Michael Gelband's CPRX Position: Q4 2025 in Review

Michael Gelband sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 152,327 shares — an estimated $3M sold.

Michael Gelband first reported a position in CPRX in Q2 2020 and held it in 11 quarters. The position peaked at $3M in Q3 2025. 374 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

Michael Gelband reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Michael Gelband sold 152,327 Catalyst Pharmaceutical shares in Q4 2025, an estimated $3M.
Michael Gelband first reported a position in Catalyst Pharmaceutical in Q2 2020 and held it in 11 quarters.
Michael Gelband's Catalyst Pharmaceutical position peaked at $3M in Q3 2025.
374 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.